- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- KHK4951, Aflibercept Injection
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 40
- States / cities
- Mesa, Arizona • Tucson, Arizona • Arcadia, California + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 121
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Fovista™, Lucentis®, Avastin®, Eylea®
- Drug
- Lead sponsor
- Retinal Consultants of Arizona
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Macular Degeneration
- Interventions
- ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
- Drug · Procedure
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
- Conditions
- Retinal Hemangioma
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- MidAtlantic Retina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Varying needle size with intravitreal ranibizumab or aflibercept
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
- Interventions
- 2-mg Intravitreous Aflibercept Injection, Prompt Vitrectomy Plus Panretinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 60
- States / cities
- Campbell, California • Glendale, California • Huntington Beach, California + 50 more
- Conditions
- Age-related Wet Macular Degeneration
- Interventions
- CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
- Drug
- Lead sponsor
- Caregen Co. Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- KHK4951, Aflibercept Injection
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 38
- States / cities
- Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
- Conditions
- Wet Macular Degeneration
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 658 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride, fluorouracil
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2014
- U.S. locations
- 3
- States / cities
- Duarte, California • Lancaster, California • South Pasadena, California
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Drug
- Lead sponsor
- Rophibio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AKST4290, Placebo, Aflibercept
- Drug
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
- Interventions
- Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Ziv-Aflibercept
- Radiation · Other · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
- Interventions
- ziv-aflibercept
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 8
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 5 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- aflibercept, High-dose aflibercept
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 84
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 913 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- La Jolla, California • Redlands, California • Santa Maria, California + 44 more